As NPY is overexpressed in ERG+ prostate cancer cells, these data provide first signs of the fact that ERG rearrangements in prostate cancer possibly modulate metabolic functions through expression of metabolic regulators like NPY. This evidence concerns the gene NPY and prostate carcinoma.